Home » ICEPHA Professors » Harald Staiger » Research

The two major foci of our research are

  • Identification of genetic variants which determine the individual treatment response to modern type-2 diabetes therapeutics, such as DPP4 inhibitors, incretin mimetics, and SGLT2 inhibitors, and
  • Identification of novel targets for type-2 diabetes therapy by molecular characterization of high-risk sub-phenotypes, like metabolically unhealthy obesity, exercise non-response, and brain insulin resistance.

Both approaches will pave the way to precision medicine in type-2 diabetes.